Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by Nailbiter2on Jan 20, 2024 4:05pm
149 Views
Post# 35837517

Global surge in cancer cases among under-50s

Global surge in cancer cases among under-50s

Global cancer cases in people under the age of 50 have risen by 79 per cent between 1990 and 2019, according to new research.

Cancer deaths in the same age group also grew by more than 27 per cent, with more than 1 million under-50s a year now dying of cancer.

Cancers of the breast, windpipe, lung, bowel and stomach are responsible for the biggest death toll.

The University of Edinburgh-led team looked at the impact of 29 cancers on people aged between 14 and 49 years-old in more than 200 countries and regions.

Their analysis found that cancer cases worldwide rose from 1.82 million in 1990 to 3.26 million in 2019.

Breast cancer accounted for the largest number of cases – 13.7 per every 100,000 people. 

The fastest rise was seen in windpipe and prostate cancers, growing 2.38 per cent and 2.23 per cent per year respectively.

The highest rates of early onset cancers in 2019 were seen in North America, Australasia, and Western Europe.

Upward trend

Based on the trends for the past three decades, researchers estimate that the global number of new early onset cancer cases and associated deaths will rise by a further 31 per cent and 21 per cent, respectively, in 2030, with those in their 40s the most at risk. 

Global surge in cancer cases among under-50s | The University of Edinburgh

<< Previous
Bullboard Posts
Next >>